Bellicum Pharmaceuticals Annual Revenue, Competitors, Number of Employees and Funding

Claim your profile

Overview

Location:
Houston, TX USA
Total Funding:$301.8M
Industry:Biotech
Founded:2003
Lead Investor(s):Citigroup, Jefferies LLC
Press
Claim your profile

City Ranking

Industry Ranking

State Ranking

Estimated Revenue & Financials

  • Bellicum Pharmaceuticals's estimated annual revenue is currently $1.1M per year.
  • Bellicum Pharmaceuticals received $Undisclosed in venture funding in April 2018.
  • Bellicum Pharmaceuticals's estimated revenue per employee is $7,568
  • Bellicum Pharmaceuticals's total funding is $301.8M.

Employee Data

  • Bellicum Pharmaceuticals has 148 Employees.
  • Bellicum Pharmaceuticals grew their employee count by -11% last year.
  • Bellicum Pharmaceuticals currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Food Safety Net...
$49.8M3215%N/A
Bellicum Pharma...
$1.1M148-11%N/A
G-CON Manufactu...
$9.5M6133%N/A
BioNews Service...
$9.3M6011%N/A
Santa Cruz Biot...
$27M174N/AN/A
Luminex Corpora...
$169.6M109410%N/A
Asuragen
N/A167N/AN/A
Family Tree DNA
$6.2M4018%N/A
XBiotech USA
$11.6M7512%N/A
VGXI, Inc. - cG...
N/A49N/AN/A
Missing a competitor? Contribute!?
Submit

Bellicum Pharmaceuticals, located near the Houston Medical Center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. We are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT) and CAR T cell therapy. We are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.

keywords:Biotechnology,Healthcare,Pharmaceuticals

148

Number of Employees

$1.1M

Revenue (est)

1

Current Jobs

-11%

Employee Growth %

$301.8M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
David SpencerChief Scientific OfficerEmail Available
Reid HuberPartner
Joseph SenesacVP Manufacturing/Viral Vector Development Email Available
Rick FairPresident & CeoEmail Available
Lucresha WilsonClinical Data Manager
Kim LuuDirectorEmail Available
Eric BourhisSenior Director Business Development & StrategyEmail Available
Pete HsuManager, Clinical Data ManagementEmail Available
Kurt MickelsonDirector - Clinical Supply ChainEmail Available
Elisabeth Madec FoleyClinical Program Manager

Bellicum Pharmaceuticals News

09/03/2019 - CORRECTING and REPLACING -Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Announces Pricing of $139.6 Million Public Offering and Private Placement. Pricing of $57.5 Million Public Offering of ...

09/08/2019 - Bellicum Pharma launches $53M equity offering

Bellicum Pharmaceuticals (NASDAQ:BLCM) is offering to sell shares of its Series 1 preferred stock and warrants to purchase common shares in ...

09/03/2019 - Bellicum Pharma (BLCM) Prices $139.6 Million Public Offering ...

Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan ...

Bellicum Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2009-10-28$4.5MAArticle
2010-12-22$3.0MUndisclosedArticle
2012-03-09$20.0MBAVG Ventures LP, Remeditex VenturesArticle
2014-01-08$34.4MBAVG VenturesArticle
2014-08-28$55.0MCMultipleArticle
2017-03-31$69.0MUndisclosedCitigroupArticle
2018-04-18$UndisclosedUndisclosedCitigroupArticle

Bellicum Pharmaceuticals Executive Hires

DateNameTitleReference
2007-10-11Amount: 3.75Round: UndisclosedArticle
2012-04-13David M. SpencerChief Scientific OfficerArticle
2014-12-08Alan MussoCFO/TreasurerArticle
2015-10-30Alan K SmithSVP ManufacturingArticle
2017-08-04Gregory NaeveChief Business OfficerArticle
2018-02-06William GrossmanChief Medical OfficerArticle
2018-05-30Shane WardGeneral Counsel and Corporate SecretaryArticle
2018-12-14Atabak MokariCFOArticle